Biotechnology company developing targeted oncology therapies.
Ikena Oncology, Inc. is a specialized oncology company dedicated to advancing targeted therapies that address specific biomarker-defined patient populations with significant unmet medical needs. The company's primary focus lies in developing innovative treatments that leverage its expertise in molecular biology and precision medicine.
At the forefront of Ikena Oncology's pipeline is IK-930, an oral small molecule inhibitor designed to target the transcriptional enhanced associate domain, a key player in the Hippo signaling pathway. This promising candidate exemplifies the company's commitment to delivering therapies that intervene at critical points in cancer biology, potentially offering new hope to patients.
In addition to IK-930, Ikena Oncology is actively advancing several other programs. These include a small molecule inhibitor program targeting ERK5 within the RAS signaling pathway, as well as IK-175, an oral inhibitor aimed at the aryl hydrocarbon receptor. Furthermore, the company is developing IK-007, an oral selective EP4 receptor antagonist tailored for the treatment of microsatellite stable colorectal cancer.
Founded in 2016 and headquartered in Boston, Massachusetts, Ikena Oncology benefits from its strategic location in a vibrant biotechnology hub. The company's cutting-edge research and development efforts underscore its mission to transform cancer treatment through precision medicine, bringing potential breakthroughs closer to patients in need.